Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Prevalence and risk factors for haematogenous periprosthetic joint infection during Staphylococcus aureus bacteraemia

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • Contributors:
      Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Section III, Infection Medicine (BMC), Airways, pathogens, innate immunity, Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper, Lund, Sektion III, Infektionsmedicin, Luftvägar, patogener, immunförsvar, Originator; Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Section III, Infection Medicine (BMC), Lunds universitet, Medicinska fakulteten, Institutionen för kliniska vetenskaper, Lund, Sektion III, Infektionsmedicin, Originator; Lund University, Faculty of Medicine, WCMM-Wallenberg Centre for Molecular Medicine, Lunds universitet, Medicinska fakulteten, WCMM- Wallenberg center för molekylär medicinsk forskning, Originator
    • نبذة مختصرة :
      Background: Staphylococcus aureus bacteraemia (SAB) may lead to periprosthetic joint infections (PJI) via haematogenous spread of bacteria to the joint. Due to the risk of PJI, patients with SAB and prosthetic joint are recommended prolonged antibiotic treatment. The aim of the study was to assess the risk of PJI during SAB, and to evaluate if short treatment duration affects outcomes in patients with uncomplicated SAB and prosthetic joints without clinical signs of PJI. Methods: Patients with growth of S. aureus in blood cultures were cross-referenced against the Swedish Arthroplasty register to identify patients with prosthetic hip or knee joints at the time of SAB. Medical records were reviewed to identify PJI at the time of SAB and during a 6-month follow-up period. Results: Out of 400 patients with SAB and a prosthetic joint, 281 met all eligibility criteria and were included in the study. Of the included participants, 35 (12%) had a haematogenous PJI. Younger age and presence of multiple prosthetic joints were associated with an increased risk of PJI. Of the 247 patients without signs of PJI at the initial SAB episode, 118 patients (48%) had an uncomplicated infection and received short total antibiotic treatment (median 15 days, IQR 13-17). The risk of PJI during the follow-up period was low (<1%) and similar in the uncomplicated group compared to patients with complicated SAB that received longer antibiotic treatment (median 29 days, IQR 15-70). Conclusion: The prevalence of haematogenous PJI was lower than previously reported. Our data do not support prolonged antibiotic treatment in patients with SAB and prosthetic joints without clinical signs of PJI.